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Abstract. Background: Cyclooxygenase-2, a key regulatory enzyme in the synthesis of the antifibrotic agent
prostaglandin E2, is downregulated in lung tissue from patients with idiopathic pulmonary fibrosis. Objective:
To investigate the association between COX2.3050 (G→ C), COX2.8473 (C→ T) and COX2.926 (G→ C)
single nucleotide polymorphisms (SNP) and the susceptibility to idiopathic pulmonary fibrosis and the pro-
gression of the disease.Design: Genetic polymorphisms were analyzed in 121 out of 225 available control sub-
jects and in all of 174 patients with idiopathic pulmonary fibrosis by real time polymerase chain reaction. Lo-
gistic regression, analysis of covariance and chi-squares test were used for statistical analysis. Results:While
analysis of disease development did not find any significant association with single SNP genotype, a haplotype
analysis revealed a strong association between the disease development and one haplotype [GC] at loci
COX2.3050 and COX2.8473, and suggested a recessive genetic effect of this haplotype. Further analysis con-
cluded that subjects having two copies of [GC] haplotype, or equivalently (GG/CC) genotype at the two SNPs,
had an increased risk after adjusting for age and sex. Due to the interaction, this elevated risk increased slowly
with age, and the estimated odds ratio (OR) decreased with age from OR = 1.4 at age 30 to OR = 1 at age 74
and OR = 0.96 at age 80. The OR was significantly greater than 1 up to age 66, and not significant for age old-
er than 66. Therefore, the recessive effect of [GC] haplotype increased the risk of IPF of subjects younger than
66 years, but its effect diminished for seniors older than 66. One hundred and forty-nine patients with idio-
pathic pulmonary fibrosis were followed up for 33.7 ± 2.1 months. Further analysis of disease progressions, de-
fined by the changes in pulmonary function tests, did not reveal any association with either SNP genotypes or
haplotypes. Conclusions: The carriage of double homozygote (GG/CC) at the SNP loci of COX2.3050 and
COX2.8473 polymorphisms may increase the susceptibility to idiopathic pulmonary fibrosis, by approximate-
ly 1.4 folds at age 30 and by a smaller fold greater than 1
up to age 66 years, but not the progression of the disease.
These findings may help to improve our understanding
of idiopathic pulmonary fibrosis pathogenesis and may
lead to the development of new therapeutic strategies.
(Sarcoidosis Vasc Diffuse Lung Dis 2010; 27: 121-130)
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Introduction
Idiopathic pulmonary fibrosis (IPF) is defined as
a specific form of chronic interstitial lung disease, as-
sociated with the histological appearance of usual in-
terstitial pneumonia (1). Although the etiology of IPF
is largely unknown, it probably involves an interaction
between environmental and genetic factors. The ge-
netic predisposition to develop pulmonary fibrosis is
suggested by the existence of familial forms of IPF.
Surfactant protein C and telomerase gene mutations
are involved in the pathogenesis of familial cases of
IPF (2, 3).However, the development of sporadic IPF
is likely to be determined by multiple genetic factors
(4). In vitro and experimental studies in animal mod-
els have shown that the pathological process of IPF is
related to the interactions of several cytokines, chem-
ical mediators and growth factors (5). Therefore, can-
didate genes may be those that regulate the processes
of inflammation, wound healing and repair.
Cyclooxygenase (COX) is the key enzyme that
mediates the synthesis of prostaglandins from
arachidonic acid. Two distinct isoenzymes of COX
have been identified. COX-1 is constitutively ex-
pressed in many tissues and it is responsible for the
production of prostaglandins in physiological func-
tions. COX-2 may be induced by the effect of a va-
riety of stimuli such as cytokines and growth factors,
and it is responsible for the production of
prostaglandins under inflammatory conditions (6).
The relevance of COX-2 in the pathogenesis of
IPF has been widely demonstrated (7-9).The down-
regulation of COX-2 expression in IPF has been as-
sociated with a failure to synthesize prostaglandin E2
(PGE2), a potent inhibitor of fibroblast proliferation
which could lead to an altered tissue repair (9-11).
We hypothesized that dysregulation of COX-2
expression in IPF may be due to genetic polymor-
phisms. The human gene encoding COX-2 is locat-
ed in chromosome 1q25.2-q25.3 (12). Several SNPs
in COX-2 gene have been identified, although only
some of them are functionally relevant (13).
While there has been no report on association
of haplotypes of COX-2 genes with IPF, it has been
reported that certain haplotype of COX-2 genes is
strongly associated with diseases in which the altered
tissue repair is a main physiopathological process,
like colorectal cancer and inflammatory bowel dis-
ease (14-15). Since alveolar epithelial wound healing
has been demonstrated to trigger lung fibrosis, we
have investigated the association of polymorphisms
and haplotypes of COX-2 gene with the develop-
ment and progression of IPF.We have selected gene
polymorphisms on the basis of reported functional
or biological relevance and/or their appreciable
prevalence in Caucasian population: COX2.3050 (G
→ C) (rs5277) located in the coding region of exon
3, COX2.8473 (C→ T) (rs5275), located in the ex-
on 10, 3´-UTR region and COX2.926 (G → C)
(rs20417) located in the promoter region. Previous
studies have shown that the selected polymorphisms
are the more prevalent and have biological relevance
in colorectal cancer, non small cell lung carcinoma
and the variability of inflammatory responses in pa-
tients subjected to coronary artery bypass graft
surgery (14, 16, 17).
Methods and materials
Subjects
White subjects from different regions of Spain
were recruited.The IPF group had 174 unrelated pa-
tients (108 men and 66 women of mean age 67.8
years ± 0.78, range 37-86 years). The control group
had 225 unrelated healthy subjects (72 men and 153
women of mean age 36.7 years ± 0.90, range 22-78
years), The control subjects were selected among
medical students, medical staffs of our medical cen-
ters and unrelated cadaveric renal allograft donors,
and were free of medical diseases and diseases relat-
ed to potential tissue fibrosis. All control subjects
were included for examining the Hardy-Weinberg
equilibrium (HWE) at the SNPs. Given that IPF
rarely develops before the age 30 and that there were
no cases younger than 30 years in this study, 104
controls younger than 30 were excluded from the
analysis of genetic association. The remaining con-
trols had 121 subjects (51 men and 70 women with
mean age 47.4 years ± 1.01, range 30-78). The rep-
resentative nature of the control group for the Span-
ish population has been previously demonstrated in
HLA genotyping studies (18). The diagnosis of IPF
was established according to the American Thoracic
Society/European Respiratory Society consensus
statement (1). Pulmonary function tests were per-
formed as previously described. Reference values
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from our own laboratory were used (19, 20). The
findings of pulmonary function tests are represented
in Table 1. The study was approved by the ethics
committees of the participating hospitals.
Identification of polymorphisms in the COX-2 gene
Genomic DNA was purified from peripheral
leukocytes by salting out. Polymorphisms
COX2.3050 (G → C) (rs5277), COX2.926 (G →
C) (rs20417) and COX2.8473 (C→ T) (rs5275) of
the COX-2 gene were assayed by means of TaqMan
SNP genotyping assays (“Assay-by-Demand”) from
Applied Biosystems (Foster City, USA). Real-time
PCR was performed in a final reaction of 25 µl,
which contained 12.5 µl of 2 Taqman Universal
Master Mix, 0.5 µl of Taqman SNP genotyping as-
say mix (Applied Biosystems), and 15 ng of genom-
ic DNA in 12 µl of distilled water. PCR amplifica-
tion and detection of amplified fragment were per-
formed on the Real-Time iCycler-IQ Bio-rad
equipment (Bio-Rad Laboratories, CA, USA). The
amplification conditions were 10 min at 95 ºC for
Amplitaq Gold activation, followed by 40 cycles of
15 sec at 92ºC for denaturation and 1 min at 60ºC
for annealing and extension. The samples were run
together with the nontemplate control in a 96-well
plate. Allelic discrimination was performed on the
post-PCR product. The fluorescence data of the
post-PCR products were analyzed directly using al-
lelic discrimination software of the Bio-rad iCycler-
IQ (Bio-Rad Laboratories, CA, USA) and present-
ed in xy scatter dot plot format. Each sample was
verified by examining the PCR curve generated to
eliminate false-positive results due to aberrant light
emission.
Statistical analysis
Single SNP genotype analysis
Using all 225 normal subjects in the control
group, the Hardy-Weinberg equilibrium (HWE)
was examined by the Chi-square test with 1 degree
of freedom (21), or by an exact test, if at least one
genotype group was found to have an expected value
less than 5.The analysis was conducted with the sta-
tistics software R using the package ‘genetics’ (22).
The single SNP genotypes and allele frequencies be-
tween groups were analyzed with logistic regression
adjusted by patient age and sex. Quantitative vari-
ables were tested with the Student´s t test or the
Wilcoxon rank sum test on the mean. The depen-
dence of the progression of IPF (changes in pul-
monary function tests) on the genotype was tested
through the analysis of covariance. The model good-
ness-of-fit was examined to ensure the validity of the
model assumption. Data were analyzed with statisti-
cal software R version 2.3.1 (The R Project for Sta-
tistical Computing), SAS Version 9.1 (SAS Institute
Inc, Cary, NC, US) and SPSS 12.0 statistical soft-
ware (SPSS Inc, Chicago, IL, US). Continuous vari-
ables are expressed as means ± SEM. p < 0.05 was
considered statistically significant.
Haplotype Analysis
Linkage disequilibrium (LD) was examined be-
tween SNPs through Chi-squares test: χ 2 = 2nD2/
(pApBpapb) ∼χ2(1) with 1 degree of freedom and the
coefficient of LD D=pABpab-paBpAb for two SNPs de-
noted as (A/a) and (B/b) SNP. Because of the phase
ambiguity of the double heterozygote, the frequen-
cies of the haplotypes were estimated through the
E-M algorithm (23). Haplotype analysis was further
conducted to examine significant linkage between
the haplotype and the disease. In general two-SNP
haplotype analysis, 9 possible genotypes (AA/BB), ...,
(aa/bb) may be formed (Table 2), and the unknown
phase of the double heterozygous genotype (Aa/Bb)
may correspond to two different diplotypes
[AB][ab] and [bb][aB], leading to 10 possible diplo-
types in general. To identify the risk haplotype H,
e.g. [AB], a powerful binary trait nucleotide (BTN)
Table 1. Pulmonary function test findings at diagnosis in patients
with idiopathic pulmonary fibrosis.
Absolute value Percent predicted
FVC, L 2.36 ± 0.05 71.55 ± 1.31
FEV1, L 1.94 ± 0.05 78,90 ± 1.42
FEV1/ FVC, % pred. 83.22 ± 0.006
TLC, L 3.93 ± 0.09 71.89 ± 1.26
DLCO, mmol/min/kPa 4.44 ± 0.12 58.23 ± 1.54
Kco, mmol/min/kPa 1.25 ± 0.03 80.25 ± 2.08
PaO2, kPa 9.98 ± 0.14
P(A-a)O2, kPa 3.68 ± 1.15
Definition of abbreviations: FVC: forced vital capacity. FEV1:
forced expiratory volume in one second. TLC: total lung capacity.
DLco: diffusion capacity of the lung for carbon monoxide; Kco: ra-
tio between DLco and alveolar volume. PaO2: partial pressure of
oxygen in arterial blood. P(A-a)O2: alveolar-arterial oxygen pres-
sure difference.
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mapping approach (24) was taken while labeling the
remaining haplotypes as non-risk haplotype. A lo-
gistic regression was employed to model the additive
and dominant effects of risk haplotypeH–, while con-
trolling the confounding variables that may poten-
tially affect the susceptibility of IPF, such as patient’s
age and sex (22, 23). (See Appendix 1). The signifi-
cance of effect estimate was further examined by the
bootstrap method with 500 bootstrap samples (25).
Results
Genotype and allele frequencies of COX-2 gene
polymorphisms in control subjects and patients with IPF
In controls, the observed genotypes did not de-
viate from the expected distribution under the
Hardy-Weinberg equilibrium in COX2. 3050 (G→
C) and COX2.8473 (C→ T) polymorphism. How-
ever, in COX2.926 (G→ C) polymorphism the ob-
served genotype in the control group deviated from
that expected under the Hardy-Weinberg equilibri-
um due to the presence of a high number of CC ho-
mozygotes. Thus, this polymorphism was excluded
from further analysis. Association analysis of disease
phenotype revealed significant associations between
disease and age and between disease and sex. How-
ever, no significant association between disease phe-
notype and genotype of individual SNP COX2.8473
or COX2.3050 was revealed through logistic regres-
sion with adjustment by age and sex. See Table 3 for
the genotype and allele frequencies as well as the p-
value for the association test. Although smoking is
Table 2.Mapping genotype into composite diplotype
Genotype Diplotype Composite
Haplotype Frequency Relative Diplotype
Configuration Freq
AA/BB [AB][AB] p 211 1 HH
AA/Bb [AB][Ab] 2p11p12 1 HH
–
AA/bb [Ab][Ab] p 212 1 H
–H–
Aa/BB [AB][aB] 2p11p21 1 HH
–
Aa/Bb [AB][ab] 2p11p22 Φ HH
–
[Ab][aB] 2p12p21 1-Φ H
–H–
Aa/bb [Ab][ab] 2p12p22 1 H
–H–
aa/BB [aB][aB] p 221 1 H
–H–
aa/Bb [aB][ab] 2p21p22 1 H
–H–
aa/bb [ab][ab] p 222 1 H
–H–
Where
Table 3.Genotype and allelic frequencies of cyclooxygenase-2 gene polymorphisms
IPF (n = 174) Controls (n = 121) P *
COX2. 8473
Genotype 0.16
CC 50.6% (88/174) 39.7% (48/121)
TT 8.1% (14/174) 14.9% (18/121)
CT 41.4% (72/174) 45.5% (55/121)
Allele
C 71.3% (248/348) 62.4% (151/242)
T 28.7% (100/348) 37.6% ( 91/242)
COX2.3050
Genotype 0.39
GG 54.6% (95/174) 63.6% (77/121)
CC 4.6% (8/174) 2.5% (3/121)
GC 40.8% (71/174) 33.9% (41/121)
Allele
G 75.0% (261/348) 80.6% (195/242)
C 25.0% ( 87/348) 19.4% ( 47/242)
Diplotype IPF (n=174) Control (n = 121) Excluded (n= 104)
(GG/CC) 25.3% (44/174) 16.5% (20/121) 18.3% (19/104)
Non (GG/CC) 74.7% (130/174) 83.5% (101/121) 81.7% (85/104)
* p value for overall difference among three SNP genotypes by logistic regression adjusting for sex and age
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well known to be associated with IPF, the heavy
missing of smoking status in our data set led to the
exclusion of smoking status from the logistic regres-
sion model for association analysis.
Association of haplotype with development of IPF
Similar to the above single SNP association, on-
ly 174 cases and 121 controls were included in the
haplotype analysis. Among the 9 possible genotypes
(Table 2), only 8 genotypes were observed, no geno-
type (CC/TT) was observed in either cases or con-
trols. Out of the 8 observed genotypes, only four
haplotypes were possible. Three haplotypes [GC],
[GT] and [CC] had a large proportion of subjects,
while the fourth haplotype [CT] had a relatively
small proportion. Therefore, the haplotype analysis
mainly focused on three haplotypes [GC], [GT] and
[CC]. The BTN mapping method identified [GC]
as a ‘risk’ haplotype while controlling for sex and age
(Table 4). Further, the effect estimates revealed that
haplotype [GC] had a significant additive effect
(p=0.0021) and a marginally significant dominant
effect (p=0.048). Further analysis revealed that the
diplotype (GG/CC), or the equivalent 2 copies of
the haplotype [GC], remained significant in associ-
ation with IPF after the Bonferroni’s correction for
multiple comparison among the genotypes of 2
copies, 1 copy and no copy of haplotype [GC]
(p=0.0039), while the 1 copy of [GC] was not sig-
nificant. The haplotypes [GT] and [CC] were not
significantly associated with the development of IPF
(p>0.05) by the same test of BTN mapping. Haplo-
type [CT] was not tested because of its low frequen-
cy in the population.
This result suggested a recessive effect of haplo-
type [GC], or the diplotype (GG/CC) that has an
observable double homozygotes. We further con-
ducted a logistic regression to estimate the effect of
diplotype (GG/CC) while adjusting for sex, age and
the interaction between the diplotype and age or sex,
and concluded that the (GG/CC) diplotype had a
significant effect (p=0.0065) as well as an interaction
effect with age (p=0.024) (Table 5). The results indi-
cated that 1) subjects having (GG/CC) diplotype
had an elevated risk for IPF up to age 66 years (Fig-
ure 1); 2) males had a higher risk than females (Fig-
ure 1); 3) the elevated risk by the (GG/CC) diplo-
type increased slowly with age (Figure 1), and the
OR decreased with age (Figure 2). This implies that
the carriers of the diplotype (GG/CC) had an ele-
vated risk than the non-carriers in the younger group
up to 66 years, and the risk elevation diminished
among older subjects over 66 years due to the dom-
inating effect of age in the development of IPF.
Relationship between genotype and allele frequencies of
COX-2 gene polymorphisms and disease progression in
patients with IPF
One hundred and forty-nine patients with IPF
were monitored for 33.7 ± 2.1 months (range 2 - 114
months), and the contact of the remaining 26 pa-
tients was lost. Overall, patients in the follow-up
Table 4.Analysis of development of idiopathic pulmonary fibrosis
with [GC] haplotype by logistic regression
Risk haplotype Parameter Estimate p-value (LR test)
[GC] Testing null hypothesis 0.049
H0: β1 = β2 = 0
β1 0.557 0.0021a
additive (0.181)
β2 0.482 0.048 b
dominant (0.244)
β3 1.022 <0.001 a
sex (0.219)
β4 0.153 <0.001 a
age (0.0096)
[GT] Testing on genetic components 0.235
null hypothesis
H0: β1 = β2 = 0
[CC] Testing on genetic components 0.75
null hypothesis
H0: β1 = β2 = 0
a. Remained significant with Bonferroni’s correction for multiple
comparison on 4 haplotypes.
b. Became not significant after Bonferroni’s adjustment for multi-
ple comparison on 4 haplotypes
Table 5. Association test on the double homozygotes (GG/CC),
age and sex with the IPF.
Parameter Estimate (Stderr) OR (95% CI) P-value
(GG/CC) 0.57 (0.21) 1.76 (1.17, 2.63) 0.0065
Sex 0.11 (0.04) 1.11 (1.02, 1.21) 0.0081
Age 0.0245 (0.002) 1.02 (1.02, 1.03) < 0.001
Age * -0.0076 (0.003) 0.992 (0.986, 0.999) 0.0237
(GG/CC)
126 A. Xaubet, W.J., M. Li, et al.
showed deterioration in pulmonary functional para-
meters. To fully determine the changes in pulmonary
function tests during the follow-up, we have ex-
pressed the changes over time with slope – change
per month of the pulmonary function tests (Table 6).
There was no significant association between the
progression of IPF and the frequencies of genotypes
and alleles (p>0.05).
Haplotype analysis of the IPF progression
Further analysis revealed no significant associa-
tion between haplotypes [GC], [GT], [CC] or the
diplotype (GG/CC) and the progression of IPF in
pulmonary function tests based on each function’s
per month change (p>0.05) (Table 7) adjusting for
the effect of sex and age. The haplotype [CT] was
not tested in this progression analysis because of the
small number of subjects having a potential [CT]
haplotype.
Fig. 1.Odds of idiopathic pulmonary fibrosis development by age
and sex.
1
2
3
4
1
2
3
4
Fig. 2. Plot of OR and 95% confidence interval by age for idio-
pathic pulmonary fibrosis development by genotype (GG/CC)
versus non-(GG/CC) (solid: OR; dash: 95% CI).
Table 6. Changes in pulmonary function tests in the follow-up
study
Variable Value
Patients, n 149
Follow-up, months 33.7 ± 2.1
FVC, (%/month)* - 0.8 ± 0.09
DLco, (%/month)* - 0.88 ± 0.19
P(A-a)O2, (kPa/month)† 0.03 ± 0.01
* Percentage change per month in FVC and DLco were calculated
by dividing the change in FVC and DLco by the follow-up period
in months for each patient
† Values are expressed as the difference in pressure (mm Hg) at the
initial assessment and the end of follow-up period divided by the
follow-up in months for each patient
Table 7.Testing on association of haplotypes with idiopathic pul-
monary fibrosis progression
Progression index Haplotype p-value of genetic effects
FVC [GC] 0.451
[GT] 0.894
[CC] 0.245
DLco [GC] 0.139
[GT] 0.409
[CC] 0.340
P (A-a) O2 [GC] 0.451
[GT] 0.561
[CC] 0.986
The association of haplotype [CT] was not studied due to small
number of subjects in the IPF progression analysis
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Discussion
The main findings of our study are as follows: a)
no specific genotype of either COX2.3050 or
COX2.8473 gene polymorphisms was associated
with the development of IPF; b) the diplotype
(GG/CC) of COX2.3050 and COX2.8473 poly-
morphisms posted significantly higher risk of devel-
opment of IPF among subjects of age 66 years or
younger. However, no genotype or haplotype was
found to be significantly associated with IPF pro-
gression. The exclusion of the 104 control subjects
younger than 30 years from the association tests
served the purpose of reducing the age confounding
effect in the analysis, and the frequency of the risk
genotype (GG/CC) among these 104 young con-
trols was found not to differ significantly from that
of the controls older than 30 years remained in the
association test.
The identification of genetic factors that predis-
pose to IPF will improve our understanding of the
disease and may lead to the development of new
therapeutic strategies. Several mediators and growth
factors are critical in the pathogenesis of IPF (5).
Therefore, variants in genes encoding these media-
tors may be involved in the predisposition and evo-
lution of IPF. Interleukin (IL)-1 receptor antagonist,
tumor necrosis factor-α (TNF-α), the carriage of
IL-6 and TNF receptor II and surfactant A and B
protein gene polymorphisms have been associated
with an increased risk of IPF. In addition, the pres-
ence of transforming growth factor β-1 (TGF β-1)
and IL-6 polymorphisms have been linked with the
decline of lung function over time (4, 26).
The relevance of COX-2 in the pathogenesis of
pulmonary fibrosis has been widely demonstrated.
Cultured fibroblasts from patients with IPF may
have a markedly reduced capacity to synthesize
PGE2 in both basal and stimulated conditions be-
cause of a down-regulation of COX-2 (9, 11, 27).
COX-2 is down-regulated in lung tissue from pa-
tients with IPF (11). COX-2 deficient mice suffer
from greater lung injury in response to fibrogenic
agents (7,9). Hodges et al (8) highlighted the im-
portance of up-regulating COX-2 and PGE2 in the
protection against fibrosis in bleomycin induced lung
fibrosis in mice. These observations suggest that the
downregulation of Cox-2 expression could play an
important role in the fibrosing process in IPF.More-
over, decreased COX-2 expression in lung parenchy-
ma has also been reported in sarcoidosis, suggesting
that it is not only characteristic of IPF but a phe-
nomenon implicated in other fibrotic lung diseases
(28). In a recent study, it has been reported that
COX-2 is up-regulated into regenerating metaplas-
tic epithelium in IPF and other interstitial lung dis-
eases, such as asbestosis and cryptogenic organizing
pneumonia suggesting that COX-2 may also partic-
ipate in the re-epithelization of the injured alveolar
walls (29).
We hypothesized that the dysregulation of
COX-2 expression in IPF may be due to the influ-
ence of genetic polymorphisms. Several SNPs in
COX-2 gene have been identified, although only a
few of them have been studied in association with
diseases (13). In our study we have selected poly-
morphisms on the basis of their reported functional
or biological relevance and/or their appreciable
prevalence in Caucasian population.
The COX2.843 polymorphism is located in the
3´-UTR region. Although it has been associated
with the risk for non-small cell lung cancer (16) and
sarcoidosis susceptibility (30), there are no data on
the possible effect of this SNP. It has been suggest-
ed that the binding of proteins to the 3´-UTR region
could regulate mRNA stability and degradation and
subsequent protein expression (16, 31].
The COX2.3050 polymorphism is one of the
most prevalent in the Caucasian population. It has
been analyzed in several pathologic disorders, and
associations with disease have been found (16, 32-
34). Recently, López-Campos et al have reported
that the carriage of the C allele is associated with
systemic sarcoidosis (35). The functional impact of
this polymorphism on COX-2 activity still remains
unknown. We hypothesized that this polymorphism
itself or with another linked marker may have bio-
logical effects on COX-2 activity.
We have found in this study that the carriage of
the double homozygote (GG/CC) of the
COX2.3050 and COX2.8473 gene polymorphisms
led to significantly increased susceptibility to IPF.
This finding is novel since there has been no report
on the association between haplotypes of COX2
genes with the development of IPF, although associ-
ations of haplotypes of COX2 genes with colorectal
cancer and inflammatory bowel disease have been
reported (14,15). In colorectal cancer, differently
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than lung fibrosis, is the presence of PGE2 directly
involved in the pathogenesis of the disease and not
its lack as it has been described in IPF. More similar
to lung fibrosis is the role played by PGE-2 in in-
flammatory bowel diseases where its reduction seems
to be involved in the pathogenic events leading to
the disease. In fact, prostaglandin E-2 exerts its ac-
tion via four different E prostanoid (EP) receptors.
EP 1-4. The EP receptor subtypes exhibit differ-
ences in regulation of PGE-2 release. (36).
The next step would be to determine how
COX2.8473 and COX2.3050 alleles may influence
the expression of COX-2 or its protein function in
relevant cells in the pathogenesis of IPF, such as
alveolar epithelial cells and fibroblasts.
We also analyzed the COX2.926 polymorphism
and did not find any differences in the distribution of
genotypes between controls and IPF patients. These
findings are of no value because the genotype distri-
bution in the control group did deviate from that ex-
pected under Hardy-Weinberg equilibrium, due to
the presence of a high number of CC homozygotes
(data not shown). Hill et al have reported that the C
allele of COX2.926 polymorphism is associated with
poor outcome and susceptibility and evolution to fi-
brosis in patients with sarcoidosis (37). The
COX2.926 polymorphism is located in the promot-
er region within a binding site for stimulatory pro-
tein-1 (Sp1), an activator of Cox- 2 gene transcrip-
tion. The presence of the polymorphism reduces the
activity of the promoter of the COX-2 gene (38). It
has been shown that the homozygous CC genotype
of the COX2.8473 polymorphism is associated with
sarcoidosis susceptibility (30). These findings, to-
gether with our results support the role of COX-2
genetic variants in the pathogenesis of various fi-
brotic interstitial diseases.
This study shows that genetic variations in
COX-2 are significantly associated with the predis-
position to develop IPF. These findings may help to
improve our understanding of IPF pathogenesis and
may lead to the development of new therapeutic
strategies.
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Appendix 1:
A logistic regression was employed to model the additive and dominant effects of risk haplotype H, patient
sex and age.
The haplotype and environmental variables age and sex are coded as follows.
where β0 is the model intercept representing the overall log-odds. β1 is the additive effect of the haplotype H,
and β2 the dominant effect. β3 is the effect of sex, β4 the age effect. The statistical expectation-maximization
algorithm was used to estimate the probability of each unknown phase by maximizing the likelihood func-
tion. The standard errors of the parameters for significant haplotypes were computed through statistical
bootstrap method with 500 bootstrap samples retaining the same numbers of cases and controls.
The disease progression indices were analyzed through a linear regression model.
where Y is the continuous response variable of disease progression index. x1…x4 are defined the same as be-
fore and
Similarly, the haplotype analysis was conducted by maximizing the likelihood function through an EM al-
gorithm for the probability of the unknown phase. The likelihood ratio test was conducted on the model pa-
rameters
for composite dyplotype HH
for composite dyplotype HH–
for composite dyplotype H–H–
for composite dyplotype HH–
otherwise
Male
Female
Treatment A
Treatment B
